Eczema, or atopic dermatitis, is a skin condition involving inflammation that leads to cracked, dry, itchy skin. Eucrisa and other PDE4 inhibitors work by slowing and stopping the action of an ...

Medically reviewed by Casey Gallagher, MDAtopic dermatitis (the most common type of eczema) causes dry, itchy skin with rough, scaly patches. It affects up to 30% of children and 10% of adults, with ...

Learn about disparities that exist in atopic dermatitis research and care, ... (Eucrisa) in white and non-white participants from two clinical trials focused on AD.

Rapid Improvement in Atopic Dermatitis With Topical PDE4 Inhibitor ... (Eucrisa), which has translated into greater in vitro potency. The 0.15% formulation was evaluated in two large, ...

How does this mechanism of action really differ from what else is on the market and even the other novel topical agent Eucrisa ... for a 16-year-old with atopic dermatitis [AD] that does not ...

Topical therapies she is using in clinical practice for atopic dermatitis (AD), including topical corticosteroids and “the newest agent on the block” Eucrisa (crisaborole, Pfizer); ...

And atopic dermatitis is a specific form of and the most common type of eczema," dermatologist Naana Boakye, MD, says. It's a widespread condition, affecting one in 10 people, ...

Casey Butrus, PharmD: Dr Keegan, explain the treatment landscape for atopic dermatitis [AD] and the therapeutic categories and options we have available for our patients. Brian Keegan, MD, PhD ...

Atopic dermatitis (AD) ... Zoryve is a phosphodiesterase-4 (PDE4) inhibitor, and this MoA has been previously seen in Pfizer’s Eucrisa (crisaborole).

Scientists continue to discover treatments for atopic dermatitis, the most common form of the skin condition eczema. They’ve learned that JAK inhibitors, once reserved for other illnesses, also ...